Ultragenyx prices gene therapy at $3.95 million
Ultragenyx has priced its newly approved gene therapy Fayuvi at $3.95 million for Sanfilippo syndrome Type A. The one-time treatment aims to halt cognitive and motor decline in pediatric patients.
Xurve View
Insights:
Xurve View
ULTRAGENYX PHARMACEUTICAL IN set a list price of $3.95 million for its newly approved gene therapy Fayuvi, launching a record-setting one-time treatment for a fatal childhood condition. The therapy addresses Sanfilippo syndrome Type A, an inherited illness that progressively destroys brain and nervous tissue in pediatric patients. The rollout arrives as families face lifetime care costs exceeding $8 million per patient.
